India plans to set up a nearly Rs 1 lakh crore (US$ 1.3 billion) fund to provide boost to companies to manufacture pharmaceutical ingredients domestically. This move comes after supply chain was disrupted due to the coronavirus pandemic exposed the country’s dependence on China and raised the threat of drug shortages.
The program consists of spending on infrastructure for drug manufacturing centers and financial incentives of up to 20 per cent of incremental sales value over the next eight years, according to a government statement.
Currently, India imports almost 70 per cent of its active pharmaceutical ingredients, the chemicals that make a finished drug work, from China. Hubei province, the epicenter of the coronavirus outbreak has been major source of these ingredients. As the world’s single largest exporter of generic drugs, India is responsible for about 20 per cent of the world’s supply.
Source: IBEF
Image Courtesy: Pharmaceutical Technology
You may also like
-
QpiAI Kaveri: India’s 64-Qubit Processor and the Rise of an Indigenous Quantum-Computing Ecosystem
-
Mission Golden Spice Launched to Build Meghalaya’s Lakadong Turmeric into a Global Premium Brand
-
ICAR-CISH–APEDA Sea Route Protocol Enables Successful Export of 12.5 Tonnes of Dashehari and Langra Mangoes to Dubai
-
PMFME Scheme Crosses Two Lakh Credit Sanctions, Strengthening Rural Food Enterprises
-
PLI Schemes Attract Over ₹2.40 Lakh Crore Investment and Generate More Than 14.15 Lakh Jobs
